In the BioHarmony Drug Report Database

"Preview" Icon

Elexacaftor

Trikafta, Kaftrio (elexacaftor) is a small molecule pharmaceutical. Elexacaftor was first approved as Trikafta on 2019-10-21. It is used to treat cystic fibrosis in the USA. It has been approved in Europe to treat cystic fibrosis. It is known to target cystic fibrosis transmembrane conductance regulator. Trikafta’s patents are valid until 2037-12-08 (FDA).

 

Trade Name

 

Kaftrio
 

Common Name

 

elexacaftor
 

ChEMBL ID

 

CHEMBL4298128
 

Indication

 

cystic fibrosis
 

Drug Class

 

Cystic fibrosis transmembrane regulator (CFTR) protein modulators

Image (chem structure or protein)

Elexacaftor structure rendering